Empagliflozin for blood vessel health in non-diabetic kidney disease
Treatments studied
Part of Heart & circulation, Kidney & urinary clinical trials.
This study tests whether a medication called empagliflozin (a type of drug that helps protect the kidneys) can improve blood vessel health in people with chronic kidney disease who do not have diabetes. It may help slow kidney decline and reduce heart risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your kidney function must be moderately reduced, with an eGFR between 20 and 59 (a blood test that measures how well your kidneys filter waste).
- You must not have diabetes (type 1 or type 2).
- You should not have taken any SGLT2 inhibitor medications (like empagliflozin) in the past year.
- You must be able to do simple physical tests like hand grip and walking.
- You must not have serious infections, skin ulcers, or a history of Fournier's gangrene.
- You must not have had a severe low blood sugar event in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This study tests a diabetes medication called empagliflozin to see if it helps improve the health of blood vessels in people with slightly elevated blood pressure. It may help protect blood vessels from damage that can lead to heart problems later.
This trial tests a medicine called empagliflozin (usually used for diabetes) to see if it can help people with very advanced kidney disease and diabetes. The study will check if this drug can slow down further kidney damage and improve overall kidney health.
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This study tests whether a medication called empagliflozin (a diabetes drug) can improve heart function in older adults with high blood pressure and obesity who are at risk for heart failure but do not have it yet. You would take the pill daily and have heart ultrasounds to check your heart's health.
Hear when a new Non-diabetic Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.